Armed with such knowledge, researchers in the field will be able to design combination therapies with checkpoint inhibitors where cancer escape/evasion can be reversed by blocking the migration and/or chemotaxis of immunosuppressive immune cell subtypes, such as monocytes, Tregs, and Th2 cells, and enhancing the infiltration of tumor-suppressive immune cell types, such as cytotoxic CD8+ T cells, Th1 cells, and DCs, by enhancing their basal migration and chemotaxis toward TMEs. The gene discussed is CD8A; the disease is cancer.